Current Status and Emerging Trends in Colorectal Cancer Screening and Diagnostics
Biosensors · 13.10.2023 · 13 (10) · 926
DOI: 10.3390/bios13100926 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biosensors, online erschienen am 13.10.2023. Verfasst von Shreya Singh Beniwal und 5 weiteren Autor:innen. Beteiligte Einrichtung: Lady Hardinge Medical College, Connaught Place, New Delhi 110001, India. Hauptthemen laut MEDLINE: Artificial Intelligence, Colorectal Neoplasms. Die Arbeit wurde bisher 62-mal zitiert (Crossref) und nennt 112 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Colorectal cancer (CRC) is a prevalent and potentially fatal disease categorized based on its high incidences and mortality rates, which raised the need for effective diagnostic strategies for the early detection and management of CRC. While there are several conventional cancer diagnostics available, they have certain limitations that hinder their effectiveness. Significant research efforts are currently being dedicated to elucidating novel methodologies that aim at comprehending the intricate molecular mechanism that underlies CRC. Recently, microfluidic diagnostics have emerged as a pivotal solution, offering non-invasive approaches to real-time monitoring of disease progression and treatment response. Microfluidic devices enable the integration of multiple sample preparation steps into a single platform, which speeds up processing and improves sensitivity. Such advancements in diagnostic technologies hold immense promise for revolutionizing the field of CRC diagnosis and enabling efficient detection and monitoring strategies. This article elucidates several of the latest developments in microfluidic technology for CRC diagnostics. In addition to the advancements in microfluidic technology for CRC diagnostics, the integration of artificial intelligence (AI) holds great promise for further enhancing diagnostic capabilities. Advancements in microfluidic systems and AI-driven approaches can revolutionize colorectal cancer diagnostics, offering accurate, efficient, and personalized strategies to improve patient outcomes and transform cancer management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Lady Hardinge Medical College, Connaught Place, New Delhi 110001, India.
- Escuela Superior de Ingeniería y Tecnología, Universidad Internacional de La Rioja, 26006 Logroño, Spain.
- NanoBioTech Laboratory, Department of Environmental Engineering, Florida Polytechnic University, Lakeland, FL 33805, USA.
- Faculty of Health Sciences, University Fernando Pessoa-Canarias, 35450 Santa Maria de Guia, Spain.
- Departments of Physiology and Biomedical Engineering, Immunology and Surgery, Microbiome Program, Center for Individualized Medicine, Mayo Clinic, Rochester, MN 55905, USA.
- School of Pharmacy, Sathyabama Institute of Science and Technology, Chennai 600 119, India.
ORCID-Profile: Shreya Singh Beniwal, Paula Lamo, Ajeet Kaushik, Dionisio Lorenzo Lorenzo-Villegas, Yuguang Liu, ArunSundar MohanaSundaram
Zitieren
APA
Beniwal, S. S., Lamo, P., Kaushik, A., Lorenzo-Villegas, D. L., Liu, Y., & MohanaSundaram, A. (2023). Current Status and Emerging Trends in Colorectal Cancer Screening and Diagnostics. Biosensors, 13(10), 926. https://doi.org/10.3390/bios13100926
Vancouver
Beniwal SS, Lamo P, Kaushik A, Lorenzo-Villegas DL, Liu Y, MohanaSundaram A. Current Status and Emerging Trends in Colorectal Cancer Screening and Diagnostics. Biosensors. 2023;13(10):926. doi:10.3390/bios13100926
BibTeX
@article{Beniwal2023,
author = {Beniwal, Shreya Singh and Lamo, Paula and Kaushik, Ajeet and Lorenzo-Villegas, Dionisio Lorenzo and Liu, Yuguang and MohanaSundaram, ArunSundar},
title = {Current Status and Emerging Trends in Colorectal Cancer Screening and Diagnostics},
journal = {Biosensors},
year = {2023},
volume = {13},
number = {10},
pages = {926},
doi = {10.3390/bios13100926}
}
EUVIMED